NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month
01 Agosto 2024 - 2:29PM
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company
focused on designing, developing, and marketing products that
improve the quality of life for patients who suffer from
neurohealth disorders, is partnering with non-profit This Is My
Brave to raise awareness and provide essential resources to support
the mental health and well-being of teens and young adults for Teen
Mental Health Month in August.
“More than 40% of high school students report feelings of
sadness or hopelessness,1 meaning the urgency to address teen
mental health and well-being has never been greater,” stated Keith
J. Sullivan, President and CEO of Neuronetics, Inc. “We’re honored
to partner with This Is My Brave to increase awareness for Teen
Mental Health Month and provide resources and education to
patients, parents, and doctors. The new indication for NeuroStar
TMS to treat adolescents aged 15 and older with depression is one
example of our commitment to the mental health needs of teens.”
NeuroStar and This Is My Brave are united in their efforts to
equip adolescents and their communities with the information,
resources, and skills to navigate mental health challenges. The
Substance Abuse and Mental Health Services Administration (SAMHSA)
reports that nearly 70% of adolescents felt a negative impact on
their mental health due to the COVID-19 pandemic,2 highlighting the
urgent need for such support. This partnership marks a pivotal step
in advocating for the official recognition of August as Teen Mental
Health Month and elevating the importance of teen mental health in
public discourse.
“We are grateful to have NeuroStar as a partner in this
endeavor. Their dedication to improving adolescent mental health
outcomes through innovative treatment and raising awareness of such
options aligns seamlessly with our goals for Teen Mental Health
Month,” said Erin Gallagher, Executive Director of This Is My
Brave. “At This Is My Brave, our goal is to provide a platform for
individuals to share their stories and foster understanding of, and
support for, mental health challenges.”
According to the Centers for Disease Control and Prevention
(CDC), suicide is the third leading cause of death among high
school-aged youths aged 15–19 years.3 Additionally, the American
Psychiatric Association (APA) indicates that 50% of mental
illnesses begin by age 14, and 75% by age 24.4 The consequences of
not addressing adolescent mental health conditions can extend into
adulthood, impairing both physical and mental health and limiting
opportunities for fulfilling lives.
For more information about This is My Brave and Teen Mental
Health Awareness Month, please visit www.thismybrave.org/tmhm. For
more information about NeuroStar TMS Therapy, please
visit www.neurostar.com.
About This Is My BraveThis Is My Brave was
co-founded in Virginia by Jennifer Marshall and Anne Marie Ames
(1958-2017), two women passionate about ending the stigma
surrounding mental illness and saving lives through storytelling.
In May of 2014, TIMB debuted its first ever live show in Arlington,
VA, at the Spectrum Theatre to a sold-out crowd of nearly 400. Over
the past ten years, the nonprofit organization has hosted 110
performances across the United States and in Australia featuring
over 1,000 storytellers. TIMB has been featured in The Washington
Post, O, The Oprah Magazine, Stage-Directions Magazine, and Health
as well as on the TODAY Show and many local media outlets. In 2019,
This Is My Brave debuted their short documentary film and launched
high school and college pilot programs, and in 2021 TIMB and
Principle Pictures launched Our Turn to Talk, a teen mental health
podcast and documentary.
About NeuroneticsNeuronetics,
Inc. believes that mental health is as important as physical
health. As a global leader in
neuroscience, Neuronetics is redefining patient and
physician expectations with its NeuroStar Advanced Therapy for
Mental Health. NeuroStar is a non-drug, noninvasive treatment that
can improve the quality of life for people suffering from
neurohealth conditions when traditional medication hasn’t helped.
NeuroStar is indicated for the treatment of depressive episodes and
for decreasing anxiety symptoms for those who may exhibit comorbid
anxiety symptoms in adult patients suffering from MDD and who
failed to achieve satisfactory improvement from previous
antidepressant medication treatment in the current episode. It is
also FDA-cleared as an adjunct for adults with obsessive-compulsive
disorder and for adolescent patients aged 15-21 with MDD. NeuroStar
Advanced Therapy is the leading TMS treatment for MDD in adults
with over 6.4 million treatments delivered. Neuronetics is
committed to transforming lives by offering an exceptional
treatment that produces extraordinary results. For safety and
prescribing information,
visit www.neurostar.com.
About Adolescent DepressionAdolescent
depression is a complex and challenging mental health condition
that affects young individuals during the crucial period of
adolescence. An estimated 4.3 million U.S. adolescents aged 15-21
are affected by MDD. Depression amongst adolescents can disrupt
crucial aspects of development, such as academic performance,
relationships with peers and family members, and overall emotional
well-being.
NeuroStar Advanced Therapy is indicated as an adjunct for the
treatment of MDD in adolescent patients aged 15-21.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Sources
- Centers for Disease Control and Prevention. (2023). Youth Risk
Behavior Surveillance System Data Summary & Trends Report:
2023. Retrieved from
https://www.cdc.gov/healthyyouth/data/yrbs/pdf/YRBS_Data-Summary-Trends_Report2023_508.pdf
- Substance Abuse and
Mental Health Services Administration. (2021). 2020 National Survey
on Drug Use and Health: The COVID-19 pandemic and substance use.
Retrieved from
https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf
- Centers for Disease
Control and Prevention. (n.d.). Adolescent health. Retrieved July
23, 2024, from
https://www.cdc.gov/nchs/fastats/adolescent-health.htm
- American Psychiatric
Association. (n.d.). Warning signs of mental illness. Retrieved
July 23, 2024, from
https://www.psychiatry.org/patients-families/warning-signs-of-mental-illness
Grafico Azioni Neuronetics (NASDAQ:STIM)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Neuronetics (NASDAQ:STIM)
Storico
Da Dic 2023 a Dic 2024